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BACKGROUND AND PURPOSE
Chronic pain is often a symptom of knee osteoarthritis (OA) for which current analgesics are either inadequate or are associated
with serious side effects. The endocannabinoid system may offer alternative targets for pain relief. We evaluated the effects of a
potent and selective monoacylglycerol (MAG) lipase inhibitor (MJN110) on OA pain behaviour, spinal mechanisms of action and
joint histopathology in the rat.
EXPERIMENTAL APPROACH
Intra-articular injection of monosodium iodoacetate (MIA) models OA pain and mimics clinical joint pathology. Effects of MJN110
on MIA-induced weight-bearing asymmetry and lowered paw withdrawal thresholds (PWTs), changes in spinal gene expression
and brain levels of relevant lipids were determined.
KEY RESULTS
Acute MJN110 (5 mg·kg1) signiﬁcantly reversed MIA-induced weight-bearing asymmetry (MIA/vehicle: 68 ± 6 g; MIA/MJN110:
35 ± 4 g) and lowered ipsilateral PWTs (MIA/vehicle: 7 ± 0.8 g; MIA/MJN110: 11 ± 0.6 g), via both CB1 and CB2 receptors.
Repeated treatment with MJN110 (5 mg·kg1) resulted in anti-nociceptive tolerance. A lower dose of MJN110 (1 mg·kg1)
acutely inhibited pain behaviour, which was maintained for 1 week of repeated administration but had no effect on joint histol-
ogy. MJN110 signiﬁcantly inhibited expression of membrane-associated PGE synthase-1 in the ipsilateral dorsal horn of the spinal
cord of MIA rats, compared with vehicle-treated MIA rats. Both doses of MJN110 signiﬁcantly elevated brain levels of the
endocannabinoid 2-arachidonoylglycerol.
CONCLUSIONS AND IMPLICATIONS
Our data support further assessment of the therapeutic potential of MAG lipase inhibitors for the treatment of OA pain.
Abbreviations
2-AG, 2-arachidonoylglycerol; AA, arachidonic acid; GFAP, glial ﬁbrillary acidic protein; MAG lipase, monoacylglycerol
lipase; MIA, monosodium iodoacetate; mPGES1, membrane-associated PGE synthase-1; OA, osteoarthritis
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Introduction
Osteoarthritis (OA) is one of the most common joint diseases
(Zhang et al., 2008) and is associated with loss of articular
cartilage, synovitis and changes in peri-articular and
subchondral bone (Goldring and Goldring, 2007). Pain is
the major symptom of OA (Chan et al., 2014), and its relief
by current analgesics is often limited by short duration of
action, or unwanted side effects. For example, despite the
promise shown by COX-2 inhibitors to reduce both inﬂam-
mation and pain in humanOA, adverse cardiovascular effects
(Juni et al., 2004) have limited their therapeutic beneﬁt. Total
knee joint replacement remains the only successful treatment
option for many OA sufferers, indicating a pressing need for
new analgesics (Glyn-Jones et al., 2015).
The endogenous cannabinoid system (ECS), which is
composed of two well-characterized receptors (CB1 and
CB2), endogenous ligands and several biosynthetic and meta-
bolic enzymes, is increasingly recognized for its ability to
modulate pain and inﬂammation, as well as its pharmacolog-
ical tractability. The ECS modulates nociceptive signalling in
numerous preclinical models of pain (see Rani Sagar et al.,
2012). Clinical applications of direct CB1 receptor agonists
indicate that ECS-targeting agents do offer therapeutic bene-
ﬁt for the treatment of pain in preclinical painmodels, as well
as in different human pain states (Elikkottil et al., 2009). The
ECS also has robust anti-inﬂammatory actions and anxiolytic
effects, which may be beneﬁcial in reducing emotional and
affective components of chronic pain (Smith and Zautra,
2008; Sinikallio et al., 2014).
Levels of endocannabinoids are elevated by noxious stim-
uli such as OA pain, in key areas involved in pain processing,
including the spinal cord (Woodhams et al., 2015). One
promising approach for harnessing the analgesic potential
of the ECS is to target the catabolic enzymes that regulate
levels of endocannabinoids. To date, there has been a
predominant focus on protecting levels of the
endocannabinoid anandamide (AEA) by the inhibition of
fatty acid amide hydrolase (FAAH); however, clinical beneﬁt
has yet to be demonstrated (see Rani Sagar et al., 2012) and a
clinical trial of an FAAH inhibitor for OA pain reported no
positive beneﬁt over placebo (Huggins et al., 2012). Unlike
AEA, the endocannabinoid 2-arachidonoylglycerol (2-AG) is
a full efﬁcacy agonist at CB1 and CB2 receptors (Savinainen
et al., 2001) and activates both CB1 and CB2 receptors with
similar potency. Exogenous 2-AG has robust anti-nociceptive
effects in models of acute and chronic pain (Woodhams et al.,
2015). Monoacylglycerol lipase (MAG lipase) plays a pivotal
role in the degradation of 2-AG, and inhibition of this
enzyme results in a signiﬁcant elevation in 2-AG in periph-
eral and central nervous tissue (Long et al., 2009). MAG lipase
activity also appears to be intricately involved in the genera-
tion of pro-inﬂammatory PGs in the CNS (Nomura et al.,
2011). MAG lipase inhibitors have anti-nociceptive effects
in models of both acute and chronic pain states (see
Ignatowska-Jankowska et al., 2015). The potential effects of
MAG lipase inhibitors on OA pain, and whether effects are
maintained upon sustained treatment, are yet to be
described.
Intra-articular injection of the metabolic inhibitor
monosodium iodoacetate (MIA) into the knee joint leads to
disruption of chondrocyte glycolysis, loss of articular carti-
lage and subchondral bone remodelling, similar to the
pathology associated with human OA (Sagar et al., 2010).
Functionally, this model of OA joint damage leads to
decreased weight-bearing on the injured knee, as seen in
human OA (Christiansen and Stevens-Lapsley, 2010), as well
as characteristics of central sensitization, including distal
allodynia, activation of spinal microglia and astrocytes and
hyper-excitability of spinal neurones, (Sagar et al., 2013).
Previously, we have reported increased expression of spinal
CB2 receptors and increased function in the MIA model of
OA pain (Burston et al., 2013). The aims of the present study
were to quantify the effects of acute and of repeated
administration of a selective MAG lipase inhibitor 2,5-
dioxopyrrolidin-1-yl 4-(bis(4-chlorophenyl)methyl)pipera-
zine-1-carboxylate (MJN110) on pain behaviour and joint
pathology and to evaluate potential mechanisms of effect at
the level of the spinal cord.
Methods
Animals
All animal care and experimental procedures were in accor-
dance with UK Home Ofﬁce Animals (Scientiﬁc Procedures)
Act (1986) and the International Association for the Study
of Pain. Animal studies are reported in compliance with the
ARRIVE guidelines (Kilkenny et al., 2010; McGrath and Lilley,
Tables of Links
TARGETS
GPCRsa Enzymesb
CB1 receptors mPGES1, membrane-bound PGE synthase-1
CB2 receptors MGL, monacylglycerol lipase
COX-2
LIGANDS
2-AG, 2-arachidonoylglycerol
Rimonabant, SR141716A
SR144528
These Tables list key protein targets and ligands in this article that are hyperlinked to corresponding entries in http://www.guidetopharmacology.org,
the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are permanently archived in the Concise Guide
to PHARMACOLOGY 2015/16 (a,bAlexander et al., 2015a,b).
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2015). Experiments were conducted in a blinded fashion
(coding was carried out by another member of the research
group), such that the person conducting pain behaviour
assessment was unaware of injury status or drug treatment
of the rats. Adult male rats (70 Sprague Dawley rats, weight
180–200 g; Charles River, UK) were used in these studies.
Intra-articular injections and behavioural
testing
Rats were anesthetized (isoﬂurane 2.5–3% in 100% O2), and
once areﬂexic received a single intra-articular injection of
1 mg MIA (Sigma, Gillingham, Dorset, UK) in 50 μL saline or
50 μL saline (control rats) through the infra-patellar ligament
of the left knee (Sagaret al., 2010). Pain behaviourwas assessed
at baseline (prior to injection, day 0). Weight distribution on
the left (ipsilateral) and right (contralateral) hindlimb was
assessed using an incapacitance tester (Linton Instrumenta-
tion Diss, Norfolk, UK), as previously described (Sagar et al.,
2010). Changes in hindpaw withdrawal thresholds were
assessed using von Frey monoﬁlaments, Linton Instrumenta-
tion Diss, Norfolk, UK (Semmes-Weinstein monoﬁlaments of
bending forces 0.4–26 g) as previously described (Sagar et al.,
2010). The lowest weight ﬁlament to elicit a withdrawal reﬂex
was taken as the hindpaw withdrawal threshold.
Acute administration of MJN110
Pain behaviour was quantiﬁed on days 3, 7, 14 and 21 post-
MIA injection. At day 21, MIA-injected rats were stratiﬁed
(by an independent experimenter) into two groups based on
pain behaviour over the previous weeks. On day 28, baseline
pain behaviour was quantiﬁed, and then rats received an i.p.
injection of either vehicle (5% ethanol, 5% emulphor and
90% sterile saline) or MJN110 (5 mg·kg1) in vehicle. Three
hours later, pain behaviour was quantiﬁed as described
previously.
The contribution of CB1 and CB2 receptors to
the anti-nociceptive effects of MJN110
Pain behaviour was quantiﬁed on days 3, 7, 10, 14 and 17
post-MIA injection. At day 17, MIA-injected rats were strati-
ﬁed (by an independent experimenter) into three groups
based on previous pain behaviour. On day 21, baseline pain
behaviour was quantiﬁed, and then rats received an i.p. injec-
tion of either vehicle (5% ethanol, 5% emulphor and 90%
sterile saline), or the CB1 receptor antagonist rimonabant
(SR141716A; 3 mg·kg1), or the CB2 receptor antagonist
SR144528 (3 mg·kg1), followed 30 min later by a second i.p.
injection of MJN110 (5 mg·kg1). Three hours later, pain
behaviour was quantiﬁed as described earlier. Doses of
antagonists were based on previous work (Ignatowska-
Jankowska et al., 2015).
Repeated administration of MJN110
Pain behaviour was quantiﬁed on days 3, 7, 10, 14 and 17
post-MIA injection. On day 17, rats were stratiﬁed based on
pain behaviour. Baseline pain behaviour was quantiﬁed on
day 21 and rats received either an i.p. injection of vehicle or
MJN110 (1 or 5 mg·kg1). Three hours later, pain behaviour
was quantiﬁed. Doses of MJN110 were based on activity-
based protein proﬁling that demonstrated maximal
reduction in activity-based probe binding to MAG lipase
by 5 mg·kg1 of MJN110, suggesting complete inhibition
of MAG lipase activity, whereas the 1 mg·kg1 of MJN110
produced a sub-maximal reduction of MAG lipase probe
binding. Rats then received daily i.p. injections of vehicle
or MJN110 (1 or 5 mg·kg1) until day 28, and pain behav-
iour was quantiﬁed on days 24 and 28.
Tissue collection
Four hours following the ﬁnal dose of MJN110, rats were
killed by cranial concussion followed by exsanguination.
Spinal cord and brain were dissected and snap frozen by
immersion in liquid nitrogen. Knee joints were collected
and stored in neutral buffered formalin.
RNA extraction and cDNA synthesis
Samples of frozen ipsilateral dorsal spinal cord tissue (about
25mg each) were homogenized in 2mL of ice cold Tri reagent
(Sigma-Aldrich, Gillingham, Dorset, UK) and RNA isolated
via separation of aqueous phase from DNA and protein
phases, followed by precipitation in a sodium acetate and
isopropanol solution before being dissolved in RNAS free
water, as previously described (Okine et al., 2012). For cDNA
synthesis, RNA was reverse transcribed as previously
described (Okine et al., 2012), using Superscript III reverse
transcriptase (Life Technologies, Paisley, UK).
Taqman quantitative real-time PCR
Gene expression was quantiﬁed utilizing the relative standard
curve method, based on Taqman quantitative real-time PCR,
as previously described (Okine et al., 2012). Primer and probe
sequences were either taken from published work (Okine
et al., 2012) or designed (see Table 1 for sequences) using primer
express version 3 (Life Technologies, UK) and synthesized by
MWG Biotech, (Ebersberg, Germany). Samples were run in
triplicate, and coefﬁcient of variation for all triplicates was
less than 10%; triplicate values were then averaged to
produce a single value per rat. Data are expressed as a ratio of
gene expression levels with reference to β-actin.
Table 1
Sequences for real-time PCR primers and probes
Gene Forward primer Reverse primer TAQMAN probe
GFAP 5-TGGCCACCAGTAACATGCAA-3 5-CAGTTGGCGGCGATAGTCAT-3 5-CAGACGTTGCTTCCCGCAACGC-3
mPGES1 5-GCGAACTGGGCCAGAACA-3 5-GGCCTACCTGGGCAAAATG-3 5-CCCCGGAGCGAATGCGTGG3
COX-1 5-GGCTGGCCGGATTGGT-3 5-ATTTCTCGGGACTCCTTGATGA-3 5-AACTTTGACTACCATGTTCTGCATGTGGCC-3
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Knee histology
Tibiofemoral joints were removed and postﬁxed in neutral
buffered formalin (Sagar et al., 2010), decalciﬁed in EDTA
and sectioned for staining with haematoxylin and eosin.
The pathology scoring was performed on stained sections,
as previously described (Sagar et al., 2014).
Chondropathy was scored (Janusz et al., 2002)on a scale of
0–5 as follows: 0, cartilage of normal appearance; 1, minimal
ﬁbrillation, superﬁcial zone only; 2, mild, extends to the
upper middle zone; 3, moderate, well into the middle zone;
4, marked, into the deep zone but not to the tidemark; and
5, severe, full thickness degeneration to tidemark. Cartilage
damage was estimated as the proportion of the section of
the medial tibial plateaux involved, 1/3, 2/3 or 3/3, and the
cartilage score multiplied by 1, 2 or 3 respectively to give a to-
tal chondropathy score.
Synovial inﬂammation was scored according to the thick-
ness of the synovial lining layer and synovial cellularity in
the medial and lateral tibiofemoral compartment (Mapp
et al., 2008) and was graded on a scale from 0 (lining cell layer
1–2 cells thick) to 3 (lining cell layer >9 cells thick and/or
severe increase in cellularity).
Measurement of 2-AG, PGE2 and arachidonic
acid (AA) in brain samples
Targeted LC-MS/MS was used for analysis of PGE2, AA and
2-arachidonoyl glycerol (2-AG) in rat brain. Samples, previously
stored at80°C, were thawed on ice and weighed accurately; in-
ternal standards 2-AG-d8 (10 μM), AA-d8 (10 μM) and PGD2-d4
(1 μM) and butylated hydroxytoluene (100 μL, 0.5%)were added
before extraction with ethyl acetate : hexane (9:1 v/v). Tissue ho-
mogenates were vortex-mixed, centrifuged (5000× g for 15 min
at 4°C), and the resulting supernatants were evaporated to
dryness. Tissue extracts were reconstituted in 200 μL of
acetonitrile : water (1:1), and 10 μL was injected for analysis by
LC-MS/MS using an Agilent 1100 series (Agilent Technologies,
Waldbronn, Germany) coupled to a Micromass Quattro
UltimaTM triple quadrupole mass spectrometer (Waters,
Manchester, UK) equippedwith electrospraynegative ionization.
The columnusedwas anACEExcel 3 μmparticle diameter, Super
C18, 150 × 2.1 mm at 40°C, and the mobile phase was a linear
gradient of water +0.02% formic acid (mobile phase A) and
acetonitrile : methanol (4:1) +0.02% formic acid (mobile phase
B). Flow rate was 300 μL·min1, and analysis time was 15 min.
Quantiﬁcation of the PGE2, AA and 2-AG was done using fully
extracted calibration standards for each of the analytes and was
performed using QuanLynx v 4.1, Waters, Manchester, UK.
Data and statistical analysis
The data and statistical analysis in this study comply with the
recommendations on experimental design and analysis in
pharmacology (Curtis et al., 2015). Results are shown as
means ± SEM. All statistics were calculated using Prism 5.0
software (Graphpad, La Jolla, USA). Data were analysed with
either one-way or two-way ANOVA, t-test, or Spearman’s corre-
lation. Data were considered signiﬁcant if P values were less
than 0.05. For data that did not pass normality testing, non-
parametric statistics were used (Kruskal–Wallis one-way
ANOVA). Correlations between rat spinal gene expression
and pain behaviour were determined with a Pearson correla-
tion. To evaluate whether the anti-nociceptive efﬁcacy of
MJN110 was reduced over time, regression analysis deter-
mined whether there was a signiﬁcant difference (P < 0.05)
from zero in the slope of the pain behaviour in the presence
of repeated MAG lipase inhibition; a signiﬁcant difference
indicated a reduction in inhibition of pain behaviour.
Materials
MJN110 was a kind gift from Micah Niphakis and Benjamin
Cravatt. MIA, Emulphore and Ethanol was purchased from
Sigma (Gillingham, Dorset, UK) were purchased from Sigma,
UK. Rimonabant and SR144528 were fromCayman Chemical
Ann Arbor, Michigan, USA.
Figure 1
Acute administration of MJN110 reverses established MIA-induced pain behaviour. Intra-articular injection of MIA was associated with a signiﬁ-
cant increase in weight-bearing asymmetry (A) and lowered hindpaw withdrawal thresholds (B). Acute systemic administration of the MAG lipase
inhibitor MJN110 (5 mg·kg1; administered on day 28) attenuatedMIA-induced changes in weight-bearing asymmetry (A) and lowered hindpaw
withdrawal thresholds (B), as denoted by the data point listed as 3 h post-MJN110. Data shown are means ± SEM; n = 6 saline groups; n = 8 rats
MIA groups; total rats used = 22. *P < 0.05, signiﬁcant difference between MIA + vehicle and saline + vehicle; #P < 0.05, signiﬁcant difference
between MIA + vehicle versus MIA + MJN110; two-way ANOVA and Bonferroni post hoc test.
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Results
Acute MAG lipase inhibition reverses
established MIA-induced pain behaviour
As previously described (Sagar et al., 2010), intra-articular
injection of MIA was associated with signiﬁcant decreases in
weight-bearing on the ipsilateral hindlimb and lowered
mechanical withdrawal thresholds of the ipsilateral hindpaw,
compared with saline-treated rats (Figure 1A, B). Acute
treatment with 5 mg·kg1 of MJN110 signiﬁcantly reversed
established MIA-induced weight-bearing asymmetry and
increased hindpaw withdrawal thresholds 3 h post-
administration (Figure 1A, B).
Contributions of CB1 and CB2 receptors to
MJN110-mediated inhibition
The ability of CB1 or CB2 receptor antagonists to block
the anti-nociceptive effects of MJN110 on pain behaviour
Figure 2
Effect of CB receptor blockade on MJN110-mediated analgesia. (A) Intra-articular injection of MIA was associated with a signiﬁcant increase
in weight-bearing asymmetry, which was reversed by a single administration of 5 mg·kg1 MJN110; this effect was blocked by the CB1 receptor
antagonist SR141716A (3 mg·kg1) and the CB2 receptor antagonist SR144528 (3 mg·kg
1). Data are mean + SEM; n = 10 rats per group.
*P < 0.05, signiﬁcant difference between MJN110 + vehicle group pre- and post-drug on day 21; +P < 0.05, signiﬁcant difference between
MJN110 + SR144528 pre- and post-drug on day 21; NS = no signiﬁcant difference between MJN110 + SR141716A pre- and post-drug on
day 21; two-way ANOVA and a Bonferroni post hoc test. (B) Intra-articular injection of MIA was associated with a signiﬁcant decrease in
ipsilateral paw withdrawal thresholds, which was reversed by a single administration of 5 mg·kg1 MJN110; this effect was blocked by the CB2
receptor antagonist SR144528 (3 mg·kg1) but not the CB1 receptor antagonist SR141716A (3 mg·kg
1). Data shown are means ± SEM; n = 10
rats per group. *P < 0.05, signiﬁcant difference between MJN110 + vehicle group pre- and post-drug on day 21; +P < 0.05, signiﬁcant difference
betweenMJN110 + SR141716A group pre- and post-drug on day 21; NS = no signiﬁcant difference betweenMJN110 + SR144528 group pre- and
post-drug on day 21; two-way ANOVA and Dunns post hoc test. (C) Analysis conducted on transformed weight-bearing data conﬁrmed that the
effects of MJN110 on MIA-induced weight-bearing asymmetry were blocked by SR141716A and SR144528. The blockade by SR144528 was less
than that produced by SR141716A. Data shown are means ± SEM; n = 10 rats per group. *P < 0.05, signiﬁcantly different fromMJN110 + Vehicle
group, #P< 0.05, signiﬁcantly different fromMJN110 + SR141716A group; two-way ANOVA and Bonferroni post hoc test. (D) Analysis conducted
on transformed ipsilateral hindpaw withdrawal threshold data (increase in paw withdrawal threshold relative to pre-drug at day 21) conﬁrmed
that the effects of MJN110 were blocked by SR144528, but not SR141716A. Data shown are means ± SEM; n = 10 rats per group. *P < 0.05,
signiﬁcantly different from MJN110 + Vehicle group, #P < 0.05, signiﬁcantly different from MJN110 + SR141716A group; one-way ANOVA
followed by Dunn’s post hoc test.
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was investigated. The anti-nociceptive effects of MJN110
(5 mg·kg1) on weight-bearing asymmetry were blocked by
the CB1 receptor antagonist SR141716A (Figure 2A, C). The
CB2 receptor antagonist SR144528 also reduced the anti-
nociceptive effects of MJN110 on weight-bearing asymmetry
(Figure 2A, C), but the magnitude of the reversal was signiﬁ-
cantly less than that achieved by SR141716A. MJN110-
mediated reversal of MIA-induced lowering of ipsilateral
hindpaw withdrawal thresholds was signiﬁcantly blocked
by the CB2 receptor antagonist SR144528, but not the CB1
receptor antagonist (Figure 2B, D).
Anti-nociceptive tolerance following repeated
administration of high-dose MJN110
Although the ﬁrst injection of 5 mg·kg1 MJN110 had robust
anti-nociceptive effects on pain behaviour (Figure 3A, B),
daily i.p. injections from days 21 to 28 post-MIA injection
induced tolerance to these anti-nociceptive effects. Regres-
sion analysis of the three time points of MJN110 dosing (days
21, 24 and 28) showed that the anti-nociceptive effects of
MJN110 on MIA-induced weight bearing were signiﬁcantly
reduced over time (F = 6345). This was also true for the effects
of repeated MJN110 treatment on hindpaw withdrawal
thresholds (F = 15 392, P < 0.05).
Repeated low-dose MJN110 exhibits sustained
anti-nociceptive effects on pain behaviour and
reduces spinal expression of mPGES1
To determine if prolonged exposure to sub-maximal doses of
MJN110 produced a sustained inhibition of pain behaviour;
the effects of repeated dosing with 1 mg·kg1 of MJN110 were
investigated. This dose of MJN110, which was previously
shown to partly inhibit brain MAG lipase in rats (Niphakis
et al., 2013), produced a signiﬁcant inhibition of pain behav-
iour (Figure 4A, B). Regression analysis of the three time
points of MJN110 dosing showed the anti-nociceptive effects
of this lower dose of MJN110 on MIA-induced weight bearing
(F = 0.003719, DFn = 1.00, DFd = 22.00), and hindpaw with-
drawal thresholds (F = 0.1477, DFn = 1.00, DFd = 22.00) did
not vary over time. As this dose of MJN110 had sustained
anti-nociceptive effects on pain behaviour until day 28,
potential effects of the intervention on the spinal expression
of pro-inﬂammatory markers and joint pathology were
evaluated.
Intra-articular injection of MIA induced a signiﬁcant
increase in the expression of the astrocyte marker glial ﬁbril-
lary acidic protein (GFAP) mRNA. MJN110 treatment did
not signiﬁcantly alter MIA-induced up-regulation of GFAP
mRNA. There was, however, a signiﬁcant difference in the
expression of membrane-associated PGE synthase-1
(mPGES1) in the MIA MJN110 group and the MIA vehicle
group (Figure 4D). Correlation analysis revealed that spinal
GFAP expression was correlated with weight-bearing
asymmetry (R2 = 0.2055) and inversely correlated with paw
withdrawal threshold (R2 = 0.2061). Spinal mPGES1 expres-
sion was correlated with weight-bearing asymmetry (R2 =
0.2055). Spinal COX-1 expression displayed a similar pattern
to mPGES1; however, groups were not signiﬁcantly different
to one another (data not shown). Spinal expression of COX-
2 mRNA was not altered (compared with saline controls) in
either the MIA vehicle or MIA MJN110 groups (Figure 4E).
Effects of repeated (1 mg·kg1) MJN110 administration on
MIA-induced cartilage damage and inﬂammation were evalu-
ated. Intra-articular injection of MIA was associated with
signiﬁcant cartilage damage (MIA + vehicle group: 8.8 ± 2
vs. saline + vehicle: 0 ± 0) and inﬂammation (MIA + vehicle
group: 1.7 ± 0.4 vs. saline + vehicle: 0 ± 0). Repeated adminis-
tration of MJN110 did not signiﬁcantly alter (worsen or
improve) the extent of cartilage damage (9.50 ± 2.38) or
inﬂammation (1.61 ± 0.49), compared with MIA + vehicle
controls.
Figure 3
Loss of the anti-nociceptive effects of 5 mg·kg1 MJN110 following repeated administration. Intra-articular injection of MIA was associated with a
signiﬁcant increase in weight-bearing asymmetry (A) and lowered hindpaw withdrawal thresholds (B). Repeated administration of the MAG lipase
inhibitor MJN110 (5 mg·kg1; administered on days 21–28) attenuated MIA-induced changes in weight bearing and lowered hindpaw with-
drawal thresholds; however, the magnitude of inhibition declined over the week of treatment. Data shown are means ± SEM; n = 8 (total rats used
=24). *P < 0.05, signiﬁcant difference between MIA + vehicle and saline + vehicle groups; #P < 0.05, signiﬁcant difference between MIA + vehicle
and MIA + MJN110; two-way ANOVA and Bonferroni post hoc test.
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Effects of MJN110 on brain levels of 2-AG, AA
and PGE2
MS analysis revealed a signiﬁcant increase in brain levels of 2-
AG following acute administration of MJN110 (5 mg·kg1)
(Figure 5A) at 4 h post-MJN110 administration. In the same
samples, levels of PGE2 were signiﬁcantly decreased
(Figure 5B), and levels of AA were unaltered (Figure 5C).
Repeated dosing of MJN110 (1 mg·kg1) was associated with
a signiﬁcant increase in brain levels of 2-AG (Figure 5D) and
a signiﬁcant reduction in levels of PGE2 (Figure 5E) but did
not alter levels of AA (Figure 5F). Repeated dosing with
MJN110 (5 mg·kg1) was also associated with a signiﬁcant
increase in brain levels of 2-AG (Figure 5G) but did not
signiﬁcantly alter levels of PGE2 (Figure 5H) or AA (Figure 5I).
Discussion
In the present study, acute inhibition of MAG lipase with
MJN110 signiﬁcantly reversed MIA-induced weight-bearing
asymmetry and MIA-induced decrease in ipsilateral paw
withdrawal thresholds. Effects were similar in magnitude to
those of nimesulide in this model of OA pain (Sagar et al.,
2011). MJN110-mediated reversal of MIA-induced weight-
bearing asymmetry was dependent on CB1, and to a smaller
extent CB2, receptor activation. In contrast, the ability of
MJN110 to reverse MIA-induced decreases in ipsilateral paw
withdrawal threshold was blocked by the CB2, but not the
CB1, receptor antagonist. This ﬁnding is consistent with the
association of lowered hindpaw withdrawal thresholds with
Figure 4
Repeated administration of 1 mg·kg1 MJN110 had sustained anti-nociceptive effects on pain behaviour and altered markers of spinal sensitiza-
tion. Intra-articular injection of MIA was associated with a signiﬁcant increase in weight-bearing asymmetry (A) and lowered hindpaw withdrawal
thresholds (B). Repeated injection of MJN110 (1 mg·kg1; administered daily from days 21 to 28) attenuated MIA-induced changes in weight-
bearing and lowered hindpaw withdrawal thresholds. Data shown are means ± SEM; n = 8 rats per group (total rats used = 24). *P < 0.05, signif-
icant difference between MIA + vehicle and saline + vehicle groups; #P < 0.05, signiﬁcant difference between MIA + vehicle and MIA + MJN110;
two-way ANOVA and Bonferroni post hoc test. (C) Intra-articular injection of MIA was associated with a signiﬁcant increase in spinal GFAP mRNA,
compared with saline-injected rats. Repeated administration of MJN110 (1 mg·kg1) did not signiﬁcantly alter MIA-induced increases in spinal
GFAP expression in the spinal cord. (D) There was no difference in spinal mPGES1 mRNA expression in MIA versus saline rats. Repeated adminis-
tration of MJN110 (1 mg·kg1) signiﬁcantly lowered spinal mPGES1 mRNA expression in MIA-treated rats (D) compared with the MIA vehicle
group. (E ) Spinal COX-2 mRNA expression was comparable between the three groups. *P < 0.05, signiﬁcantly different as indicated; two-way
ANOVA and Bonferroni post hoc test.
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central sensitization and our earlier demonstration that the
MIA model is associated with a signiﬁcant increase in spinal
CB2 receptor expression and alterations in CB2 receptor
signalling as measured by spinal electrophysiology (Burston
et al., 2013). The magnitude of inhibition by the MAG lipase
inhibitor was comparable to the anti-nociceptive effects seen
with FAAH inhibitors in acute inﬂammatory, neuropathic
(Sasso et al., 2012) and arthritic pain (Kinsey et al., 2011).
Repeated treatment with the higher dose of MJN110
(5 mg·kg1) resulted in a loss of anti-nociceptive efﬁcacy,
whereas the lower dose (1 mg·kg1) had sustained anti-
nociceptive effects on pain behaviour in the MIA model over
the course of the study. It is, of course, possible that over
longer periods of repeated dosing, tolerance may develop.
Repeated treatment with MJN110 (1 mg·kg1) did not alter
the extent of MIA-induced joint cartilage damage or joint
inﬂammation, suggesting that blockade of MAG lipase does
not alter this aspect of the model of OA, or possibly that by
day 21 post-MIA injection, knee pathology is already fully
established and is no longer reversible.
Repeated treatment with MJN110 (1 mg·kg1) signiﬁ-
cantly reduced expression of mPGES1 (the enzyme involved
in the conversion of the COX metabolite, PGH2 to PGE2) in
the dorsal horn of the spinal cord in MIA rats, compared with
controls. These data plus the effects of MJN110 on hindpaw
withdrawal thresholds, and the lack of effect on joint pathol-
ogy, suggest that systemically administered MJN110 modu-
lates OA pain behaviour via a spinal or supraspinal
Figure 5
MJN110 elevates whole brain levels of 2-AG and reduces levels of PGE2. Acute administration of MJN1110 (5 mg·kg1) elevated levels of 2-AG (A),
reduced levels of PGE2 (B) but did not alter levels of AA levels (C). Chronic administration of MJN110 (1 mg·kg1) elevated levels of 2-AG (D), re-
duced levels of PGE2 (E) but did not alter levels of AA (F). Chronic administration of MJN110 (5 mg·kg1) elevated levels of 2-AG (G) but did not
alter levels of PGE2 (H) or alter levels of AA (I). Data shown are means ± SEM; n = 4–6 rats per group. *P< 0.05, signiﬁcantly different from vehicle;
unpaired t-tests.
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mechanism of action. Nevertheless, we have only evaluated
the effect of two doses of MJN110 in this model, and there-
fore, a dose-response relationship for analgesia or other
parameters in this model has not been established.
To ascertain whether the effects of MJN110 were likely to
be mediated by a change in bioactive lipids, we quantiﬁed
brain levels of 2-AG, PGE2 and AA. In keeping with a previous
study (Parker et al., 2015), acute administration of MJN110
(5 mg·kg1) and chronic administration of the lower dose of
MJN110 (1 mg·kg1) were associated with increased brain
levels of 2-AG and a reduction in levels of PGE2 at 4 h post-
administration. Chronic administration of the higher dose
of MJN110 (5 mg·kg1) increased brain levels of 2-AG but
had no effect on PGE2 levels. None of the treatments altered
brain levels of AA.
2-AG-induced analgesia has been described in models of
acute and chronic pain (see Woodhams et al., 2015). The
differential effects of the two doses of MJN110 on OA pain
behaviour reported here are consistent with the reported
maximal and sub-maximal blockade of MAG lipase by the
two doses of MJN110, where only the former causes desensiti-
zation due to down-regulation of CB1 receptors (Schlosburg
et al., 2010). Our demonstration of anti-nociceptive tolerance
of the higher dose of MJN110 supports the contribution of
CB1 receptor-mediated mechanisms to the anti-nociceptive
effects of MJN110 in this model of OA pain.
Recent studies have advanced understanding of the spinal
mechanisms contributing to OA pain behaviour, demonstrat-
ing important contributions of dorsal horn neuronal excit-
ability (Sagar et al., 2010; Kelly et al., 2013) and activation of
spinal glia cells (Lee et al., 2011; Sagar et al., 2011; Ogbonna
et al., 2013; Yu et al., 2013) (see references in Rani Sagar
et al., 2012). In the present study, repeated MJN110 treatment
did not signiﬁcantly inhibit MIA-induced increases in GFAP
mRNA in the dorsal horn of the spinal cord, which contrasts
with the reported effects of an exogenous cannabinoid ligand
selective for the CB2 receptor (Burston et al., 2013). These
differences between the effects of an exogenous CB2 ligand
and those of MAG lipase inhibition on this spinal marker
of astroglyosis may reﬂect differences in the study design
(preventative treatment strategy vs. therapeutic herein) or
differences between binding afﬁnities of the CB2 ligand and
that of 2-AG (Huffman et al., 1999; Gonsiorek et al., 2000).
Inhibition of MAG lipase reduced the AA substrate pool
for PG production and decreased production of pro-
inﬂammatory mediators in the brain (Nomura et al., 2011;
Chen et al., 2012; Lysenko et al., 2014; Zhang et al., 2015).
In the present study, repeated treatment with the lower dose
of MJN110 signiﬁcantly reduced expression of spinal
mPGES1 in MIA-injected rats, compared with vehicle treat-
ment and signiﬁcantly decreased levels of PGE2 in the brain.
Given that mPGES1 plays a major role in the production of
pro-inﬂammatory and pro-nociceptive PGE2, our data
suggest that the anti-nociceptive effects of MJN110 may be,
at least in part, mediated by the modulation of the PG system
in the spinal cord and brain. Experimental constraints meant
that spinal cord tissue was not available for MS analysis. With
the assumption that the effects of MJN110 on MAG lipase in
the spinal cord and brain are comparable, our demonstration
that chronic MJN110 administration reduced levels of PGE2
in the brain further strengthens the evidence that the anti-
nociceptive effects of MJN110 are mediated by both an eleva-
tion of 2-AG and activation of CB receptors and a reduction in
synthesis (via decreased mPGES1 expression) or the produc-
tion of PGE2 from metabolic substrates in the spinal cord.
In summary, our experiments have shown that MAG
lipase inhibition had signiﬁcant beneﬁcial effects on
established pain behaviour and was associated with a reduc-
tion in spinal pro-inﬂammatory gene expression, an eleva-
tion of 2-AG and a reduction in PGE2 in the brain. These
new ﬁndings support the further investigation of MAG lipase
as a target for the treatment of OA pain.
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